• Find People
  • Campus Map
  • PiratePort
  • A-Z
    • About
    • Submit
    • Browse
    • Login
    View Item 
    •   ScholarShip Home
    • Other Campus Research
    • Open Access
    • View Item
    •   ScholarShip Home
    • Other Campus Research
    • Open Access
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of The ScholarShipCommunities & CollectionsDateAuthorsTitlesSubjectsTypeDate SubmittedThis CollectionDateAuthorsTitlesSubjectsTypeDate Submitted

    My Account

    Login

    Statistics

    View Google Analytics Statistics

    Targeted therapy for hepatocellular carcinoma: Novel agents on the horizon

    Thumbnail
    View/ Open
    oncotarget-03-236.pdf (1.263Mb)

    Show full item record
    
    Author
    Cervello, Melchiorre; McCubrey, James A.; Cusimano, Antonella; Lampiasi, Nadia; Azzolina, Antonina; Montalto, Giuseppe
    Abstract
    Hepatocellular carcinoma (HCC) is the most common liver cancer, accounting for 90% of primary liver cancers. In the last decade it has become one of the most frequently occurring tumors worldwide and is also considered to be the most lethal of the cancer systems, accounting for approximately one third of all malignancies. Although the clinical diagnosis and management of early-stage HCC has improved significantly, HCC prognosis is still extremely poor. Furthermore, advanced HCC is a highly aggressive tumor with a poor or no response to common therapies. Therefore, new effective and well-tolerated therapy strategies are urgently needed. Targeted therapies have entered the field of anti-neoplastic treatment and are being used on their own or in combination with conventional chemotherapy drugs. Molecular-targeted therapy holds great promise in the treatment of HCC. A new therapeutic opportunity for advanced HCC is the use of sorafenib (Nexavar). On the basis of the recent large randomized phase III study, the Sorafenib HCC Assessment Randomized Protocol (SHARP), sorafenib has been approved by the FDA for the treatment of advanced HCC. Sorafenib showed to be able to significantly increase survival in patients with advanced HCC, establishing a new standard of care. Despite this promising breakthrough, patients with HCC still have a dismal prognosis, as it is currently the major cause of death in cirrhotic patients. Nevertheless, the successful results of the SHARP trial underscore the need for a comprehensive understanding of the molecular pathogenesis of this devastating disease. In this review we summarize the most important studies on the signaling pathways implicated in the pathogenesis of HCC, as well as the newest emerging drugs and their potential use in HCC management.
    URI
    http://hdl.handle.net/10342/7914
    Subject
    HCC, targeted therapy, VEGF, Ras/Raf/MEK/ERK, PI3K/Akt/PTEN/mTOR, signal transduction inhibitors, cancer
    Date
    2012-03-31
    Citation:
    APA:
    Cervello, Melchiorre, & McCubrey, James A., & Cusimano, Antonella, & Lampiasi, Nadia, & Azzolina, Antonina, & Montalto, Giuseppe. (March 2012). Targeted therapy for hepatocellular carcinoma: Novel agents on the horizon. Oncotarget, (3:3), p.236-260. Retrieved from http://hdl.handle.net/10342/7914

    Display/Hide MLA, Chicago and APA citation formats.

    MLA:
    Cervello, Melchiorre, and McCubrey, James A., and Cusimano, Antonella, and Lampiasi, Nadia, and Azzolina, Antonina, and Montalto, Giuseppe. "Targeted therapy for hepatocellular carcinoma: Novel agents on the horizon". Oncotarget. 3:3. (236-260.), March 2012. March 03, 2021. http://hdl.handle.net/10342/7914.
    Chicago:
    Cervello, Melchiorre and McCubrey, James A. and Cusimano, Antonella and Lampiasi, Nadia and Azzolina, Antonina and Montalto, Giuseppe, "Targeted therapy for hepatocellular carcinoma: Novel agents on the horizon," Oncotarget 3, no. 3 (March 2012), http://hdl.handle.net/10342/7914 (accessed March 03, 2021).
    AMA:
    Cervello, Melchiorre, McCubrey, James A., Cusimano, Antonella, Lampiasi, Nadia, Azzolina, Antonina, Montalto, Giuseppe. Targeted therapy for hepatocellular carcinoma: Novel agents on the horizon. Oncotarget. March 2012; 3(3) 236-260. http://hdl.handle.net/10342/7914. Accessed March 03, 2021.
    Collections
    • Open Access

    xmlui.ArtifactBrowser.ItemViewer.elsevier_entitlement

    East Carolina University has created ScholarShip, a digital archive for the scholarly output of the ECU community.

    • About
    • Contact Us
    • Send Feedback